FILING ANALYSIS · THURSDAY, OCTOBER 15
Tonix Pharmaceuticals Holding Corp. TNXP — 8-K: Results of Operations and Financial Condition
neutral
Tonix Pharmaceuticals disclosed preliminary Q3 results with net revenue from TONMYA estimated between $14.0 million and $15.0 million and cash and cash equivalents of approximately $162.8 million, but the information is subject to revision and should be viewed with caution.
The filing
8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →